The choice of discovery technology is a critical determinant of market success in 2025. According to a Antibody Drug Discovery Market Analysis, the Phage Display segment continues to dominate the technical landscape, projected to account for a 50.3% share by 2035. Its popularity stems from its ability to produce high-affinity human antibodies rapidly without the ethical and logistical hurdles of animal immunization.

However, Hybridoma Technology remains resilient, particularly in the production of monoclonal antibodies for research and diagnostic use, maintaining a 35% share of the services market. In 2025, the fastest-growing sub-segment is Transgenic Animal Models (such as the HUGO-Ab or Harbour Mice), which allow for the direct generation of fully human antibodies in an in vivo environment. These models are highly prized because they produce antibodies that have already undergone natural "safety filtering" within a living system, often resulting in better developability profiles.

Furthermore, Single B-Cell Cloning is seeing a surge in adoption for rapid-response scenarios. By isolating individual B-cells from human donors, companies can now recover functional antibodies in weeks. In late 2025, the validation of these methods in infectious disease and neurology—specifically for antibodies that can cross the blood-brain barrier—is opening new frontiers for the treatment of Alzheimer's and Parkinson's disease.

FAQ: Which discovery method is most popular? Ans: Phage Display is currently the dominant method (expected 50.3% share), though Transgenic Animal Models and Single B-Cell Cloning are growing rapidly for human antibody production.